newsfilter
← Latest News
PR Newswire·

A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

  • Avaí Bio, Inc. (OTCQB: AVAI) & its joint-venture partner Austrianova reached an agreement in principle with an internationally acclaimed partner to supply insulin-producing cells for their Insulinova diabetes therapy.
  • Insulinova is a late-2025 joint venture combining Avaí's cell-programming process with Austrianova's Cell-in-a-Box® encapsulation technology to create a glucose-responsive insulin alternative.
  • The therapy aims to treat type 1 & insulin-dependent type 2 diabetes by implanting encapsulated cells that produce insulin without triggering immune rejection.
  • CEO Chris Winter stated securing a world-class cell supplier is a critical milestone for advancing the program toward restoring natural insulin production.
  • The agreement remains subject to the execution of definitive documents & customary closing conditions, which Avaí expects to finalize in the coming days.
  • The article highlights Vertex Pharmaceuticals (Nasdaq: VRTX) as a leader in stem-cell-derived islet therapy aiming for regulatory submissions in 2026.
  • Eledon Pharmaceuticals (Nasdaq: ELDN) is developing tegoprubart to prevent immune rejection of transplanted tissue without heavy immunosuppression.
  • Sernova Biotherapeutics (OTC: SEOVF) utilizes a similar implantable "bio-hybrid organ" approach & received FDA orphan drug designation in June 2026.
  • Viking Therapeutics (Nasdaq: VKTX) is noted for its GLP-1-based metabolic treatments, reflecting strong investor demand in the diabetes sector.
  • Insulinova remains in the preclinical stage, & the cell-supply deal does not guarantee final closing or future clinical success.
  • The publisher, American News Group, disclosed a financial conflict of interest due to prior compensation & share ownership in Avaí Bio, Inc.